Automated Urinary Chemokine Assays for Noninvasive Detection of Kidney Transplant Rejection: A Prospective Cohort Study
- PMID: 37777058
- DOI: 10.1053/j.ajkd.2023.07.022
Automated Urinary Chemokine Assays for Noninvasive Detection of Kidney Transplant Rejection: A Prospective Cohort Study
Abstract
Rationale & objective: Prior studies have demonstrated the diagnostic potential of urinary chemokines C-X-C motif ligand 9 (CXCL9) and CXCL10 for kidney transplant rejection. However, their benefit in addition to clinical information has not been demonstrated. We evaluated the diagnostic performance for detecting acute rejection of urinary CXCL9 and CXCL10 when integrated with clinical information.
Study design: Single-center prospective cohort study.
Setting & participants: We analyzed 1,559 biopsy-paired urinary samples from 622 kidney transplants performed between April 2013 and July 2019 at a single transplant center in Belgium. External validation was performed in 986 biopsy-paired urinary samples.
Tests compared: We quantified urinary CXCL9 (uCXCL9) and CXCL10 (uCXCL10) using an automated immunoassay platform and normalized the values to urinary creatinine. Urinary chemokines were incorporated into a multivariable model with routine clinical markers (estimated glomerular filtration rate, donor-specific antibodies, and polyoma viremia) (integrated model). This model was then compared with the tissue diagnosis according to the Banff classification for acute rejection.
Outcome: Acute rejection detected on kidney biopsy using the Banff classification.
Results: Chemokines integrated with routine clinical markers had high diagnostic value for detection of acute rejection (n=150) (receiver operating characteristic area under the curve 81.3% [95% CI, 77.6-85.0]). The integrated model would help avoid 59 protocol biopsies per 100 patients when the risk for rejection is predicted to be below 10%. The performance of the integrated model was similar in the external validation cohort.
Limitations: The cross-sectional nature obviates investigating the evolution over time and prediction of future rejection.
Conclusions: The use of an integrated model of urinary chemokines and clinical markers for noninvasive monitoring of rejection could enable a reduction in the number of biopsies. Urinary chemokines may be useful noninvasive biomarkers whose use should be further studied in prospective randomized trials to clarify their role in guiding clinical care and the use of biopsies to detect rejection after kidney transplantation.
Plain-language summary: Urinary chemokines CXCL9 and CXCL10 have been suggested to be good noninvasive biomarkers of kidney transplant rejection. However, defining a context of use and integration with clinical information is necessary before clinical implementation can begin. In this study, we demonstrated that urinary chemokines CXCL9 and CXCL10, together with clinical information, have substantial diagnostic accuracy for the detection of acute kidney transplant rejection. Application of urinary chemokines together with clinical information may guide biopsy practices following kidney transplantation and potentially reduce the need for kidney transplant biopsies.
Keywords: Acute rejection; biomarker; chemokines; kidney transplantation.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection.J Am Soc Nephrol. 2015 Nov;26(11):2840-51. doi: 10.1681/ASN.2014080797. Epub 2015 May 6. J Am Soc Nephrol. 2015. PMID: 25948873 Free PMC article.
-
Optimizing the approach to monitoring allograft inflammation using serial urinary CXCL10/creatinine testing in pediatric kidney transplant recipients.Pediatr Transplant. 2024 May;28(3):e14718. doi: 10.1111/petr.14718. Pediatr Transplant. 2024. PMID: 38553815
-
Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection.Am J Transplant. 2020 Dec;20(12):3462-3476. doi: 10.1111/ajt.15959. Epub 2020 Jun 27. Am J Transplant. 2020. PMID: 32342614
-
Urinary Cell mRNA Profiles Predictive of Human Kidney Allograft Status.Clin J Am Soc Nephrol. 2021 Oct;16(10):1565-1577. doi: 10.2215/CJN.14010820. Epub 2021 Apr 27. Clin J Am Soc Nephrol. 2021. PMID: 33906907 Free PMC article. Review.
-
A critical review of biomarkers in kidney transplantation.Curr Opin Nephrol Hypertens. 2017 Nov;26(6):509-515. doi: 10.1097/MNH.0000000000000361. Curr Opin Nephrol Hypertens. 2017. PMID: 28857783 Review.
Cited by
-
Urinary CXCL-10, a prognostic biomarker for kidney graft injuries: a systematic review and meta-analysis.BMC Nephrol. 2024 Sep 4;25(1):292. doi: 10.1186/s12882-024-03728-2. BMC Nephrol. 2024. PMID: 39232662 Free PMC article. Review.
-
Transforming kidney transplant monitoring with urine CXCL9 and CXCL10: practical clinical implementation.Sci Rep. 2024 Sep 2;14(1):20357. doi: 10.1038/s41598-024-70390-x. Sci Rep. 2024. PMID: 39223175 Free PMC article.
-
Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications.Transpl Int. 2024 Aug 12;37:13239. doi: 10.3389/ti.2024.13239. eCollection 2024. Transpl Int. 2024. PMID: 39188271 Free PMC article. Review.
-
Toward Precision Medicine: Exploring the Landscape of Biomarkers in Acute Kidney Injury.Biomolecules. 2024 Jan 8;14(1):82. doi: 10.3390/biom14010082. Biomolecules. 2024. PMID: 38254682 Free PMC article. Review.
-
Urine CXCL10 as a biomarker in kidney transplantation.Curr Opin Organ Transplant. 2024 Apr 1;29(2):138-143. doi: 10.1097/MOT.0000000000001135. Epub 2024 Jan 19. Curr Opin Organ Transplant. 2024. PMID: 38235748 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous